TTB-36220-20003
4 vaccinations
1 coded response
43 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 234 / VA
- Registered
- 2021-01-27
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-27
Registered in v-safe
-
2021-01-27
Dose 1 — Pfizer-BioNTech
- 2021-01-27
- 2021-01-28
- 2021-01-29
- 2021-01-31
- 2021-02-01
- 2021-02-02
- 2021-02-03
- 2021-02-10
-
2021-02-16
Dose 2 — Pfizer-BioNTech
-
2021-02-17
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness · Be unable to workAdult check-in
- 2021-02-18
- 2021-02-19
- 2021-02-20
- 2021-02-21
- 2021-02-22
- 2021-02-23
- 2021-03-02
- 2021-03-09
- 2021-03-16
- 2021-03-23
- 2021-03-30
- 2021-05-19
- 2021-08-17
-
2021-11-13
Dose 3 — Pfizer-BioNTech
-
2021-11-14
Health check-in — days 1–6 daily, dose 3Feeling: Good · Site: Pain · Fever · Headache, Fatigue or tirednessAdult check-in
- 2021-11-15
- 2021-11-16
- 2021-11-17
- 2021-11-18
- 2021-11-19
- 2021-11-20
- 2021-11-27
- 2021-12-04
- 2021-12-11
- 2021-12-18
- 2021-12-26
- 2022-02-12
- 2022-05-15
-
2022-09-26
Dose 4 — Pfizer-BioNTech
- 2022-10-14
- 2022-10-17
- 2022-10-24
- 2022-10-31
- 2022-11-07
-
2022-12-26
Survey response — 3 months, dose 4MedDRA: Arteriovenous malformation, Haemorrhage, Retained products of conception — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Retained products of conception, AVM of uterus, significant blood lossMedDRA releases: 2024-11 · check-in free text available
- 2023-03-27
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-27 | Pfizer-BioNTech | |
| 2 | 2021-02-16 | Pfizer-BioNTech | |
| 3 | 2021-11-13 | Pfizer-BioNTech | No |
| 4 | 2022-09-26 | Pfizer-BioNTech | No |
Free text
Release 12 — 3 months, dose 4
Symptoms: Retained products of conception, AVM of uterus, significant blood loss
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Arteriovenous malformation | · | · | ✓ |
| SD | Haemorrhage | · | · | ✓ |
| SD | Retained products of conception | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release